In this article, we show the general relation between standardization methods and marginal structural models. Standardization has been recognized as a method to control confounding and to estimate causal parameters of interest. Because standardization requires stratification by confounders, the sparse-data problem will occur when stratified by many confounders and one then might have an unstable estimator. A new class of causal models called marginal structural models has recently been proposed. In marginal structural models, the parameters are consistently estimated by the inverseprobability-of-treatment weighting method. Marginal structural models give a nonparametric standardization using the total group (exposed and unexposed) as the standard. In epidemiologic analysis, it is also important to know the change in the average risk of the exposed (or the unexposed) subgroup produced by exposure, which corresponds to the exposed (or the unexposed) group as the standard. We propose modifications of the weights in the marginal structural models, which give the nonparametric estimation of standardized parameters. With the proposed weights, we can use the marginal structural models as a useful tool for the nonparametric multivariate standardization.
S tandardization methods have been used in epidemiology for a long time. 1, 2 The related idea of calculating the expected number of deaths goes back to 18th century actuarial mathematicians. 3 Standardization methods are used to control confounding, and one can estimate causal parameters of interest through standardization. [4] [5] [6] [7] Standardized estimators, such as the standardized mortality/morbidity ratio (SMR), are calculated by stratification on a set of confounding factors.
When the number of confounding factors used in stratification is increased, the data become sparse. In that case, estimated standardized parameters tend to be unstable. To alleviate this lack of stability, parametric model-based standardization methods have been proposed. 8, 9 These methods depend heavily on the correct specification of the parametric model forms, which are usually unknown in epidemiologic applications.
Recently, Robins and colleagues 10, 11 have proposed a new class of causal models called marginal structural models. Their weighted analysis gives an asymptotically unbiased estimate of the causal parameter of interest with the inverse of the conditional probability of receiving the subject's own exposure or treatment as a weight. As given in Appendix 1 by Robins et al., 10 in a simple stratified point exposure analysis, their estimator is identical to the standardized estimator with the total group as the standard population. Hence, the marginal structural model is interpretable as a nonparametric multivariate standardization method.
In this article, we propose to use different sets of weights in the marginal structural models. The proposed approach gives the general standardization framework in the context of the marginal structural models.
Methods of Standardization
Suppose the data are stratified by combinations of multiple confounding factors or a propensity score. 5, 12 Table  1 gives the data layout in the kth stratum. The second row (x k , y k ) denotes pairs of the number of outcome events (eg, deaths) among the exposed and the unexposed. The last row (n, m k ) denotes pairs of the exposed and the unexposed subjects in the risk ratio estimation, or pairs of the exposed and the unexposed person-time denominators in the rate ratio estimation.
To illustrate standardization methods, we use an example of the effect of tamoxifen use (exposed: TAM ϭ 1, unexposed: TAM ϭ 0) on the recurrence of breast cancer (recurrence: RECUR ϭ 1, no recurrence: RECUR ϭ 0). Detailed multivariate person-time analysis is given in a later section. Table 2 shows the crude data and the data stratified by lymph node metastasis at surgery (positive: LYM ϭ 1, negative: LYM ϭ 0). No effect of tamoxifen was observed in the crude data (the crude risk ratio is 1.01). However, possible protective effects and effect-measure modification were observed in the stratified data (the stratum-specific risk ratios are 0.91 and 0.67, respectively).
When the target population of the study is the exposed group and one needs to summarize the overall effect of exposure in the ratio scale, the standardized mortality/ morbidity ratio (SMR) is such a measure, which is given by:
The numerator of SMR can be interpreted as the number of deaths (or events) in the exposed group when the exposed group was actually exposed, which is identical to the observed number of deaths. In contrast, the denominator can be interpreted as the expected number of deaths in the exposed group if the exposed group had not been exposed. 4, 6 Note that this expectation is not the null (no effect) expectation, which is given by ⌺ k n k t k /N k , where t k ϭ x k ϩ y k and N k ϭ n k ϩ m k . It is instead the counterfactual number of deaths as if the exposed had not been exposed, because in the kth stratum we could substitute y k /m k for the counterfactual disease frequency in the exposed when confounding is removed by stratification. 6 In the example in Table 2 , SMR is calculated by: The SMR is interpreted as the proportionate change in risk (or rate) of the exposed group produced by exposure. In the calculation of SMR, the exposed group is used as the standard population. This is also known as the indirect standardization.
Other choices of target population that are commonly used in epidemiologic studies are the unexposed group and the total group (combining the exposed and the unexposed groups). 13 When the unexposed group is the target population and is chosen as the standard population, the standardized risk (or rate) ratio in the unexposed is given by:
This is known as the direct standardization. In our example, it is calculated as: LYM ϭ 1 (positive for lymph node metastasis at surgery), 0 (negative); TAM ϭ 1 (exposed to tamoxifen), 0 (unexposed); RECUR ϭ 1 (recurrence of breast cancer). SRR U is interpreted as the proportionate change in the risk (or rate) that would have occurred in the unexposed group had they been exposed. When the total group (combining the exposed and the unexposed) is the target population, the standardized risk (or rate) ratio in the total group,
is calculated as: The interpretations of these standardized parameters are still valid even when there is effect-measure modification. In other words, stratum specific ratios are heterogeneous.
Marginal Structural Models and Standardization
We explain the marginal structural models in the context of causal risk ratio estimation. Application to the estimation of other effect measures is straightforward. 10 In the estimation of the effect of a dichotomous exposure E (1: exposed, 0: unexposed) on a dichotomous outcome D (1: event occurred, 0: no event), we consider the contrast of the following potentially counterfactual probabilities:
for the probability of D ϭ 1 if everyone in the target population had been exposed ("set E ϭ 1") and if everyone in the target population had not been exposed ("set E ϭ 0"). 2, 7 Note that the counterfactual probability, P(D ϭ 1|set E ϭ e), can be different from the observed probability, P(D ϭ 1|E ϭ e), because the latter refers to a subset of population members with E ϭ e, whereas the former refers to all population members.
In the marginal structural models, the marginal distribution of the counterfactual probabilities is modeled as:
where exp(␣ 1 ) is the causal risk ratio. The corresponding loglinear model for the observed probability can be written as:
where exp( 1 ) is the crude risk ratio. This is an association model. Because this model is for the observed data, asymptotically unbiased estimates for the association parameters 0 and 1 are obtained through standard statistical software. However, the association parameter 1 will differ from the causal parameter ␣ 1 except when exposure is unconfounded. Robins et al. 10 have proposed a weighted analysis procedure for this association model, which in turn gives unbiased estimates of causal parameter ␣ 1 . First, we assume that we have no unmeasured confounders given data on measured confounders Z. Next, we assign a weight w Ti to each subject i which is equal to the inverse of the conditional probability of receiving the subject's own exposure e i conditional on the subject's confounder information z i , P(E|Z). With these weights, we perform the weighted analysis of the association model. Because the propensity score is defined as the conditional probability of receiving exposure, P(E ϭ 1|Z ϭ z i ), 5 the weights for the exposed subjects are the inverse of P(E ϭ 1|Z ϭ z i ) and those for the unexposed subjects the inverse of P(E ϭ 0|Z ϭ z i ) ϭ 1 Ϫ P(E ϭ 1|Z ϭ z i ). The resultant estimator is called the inverse probability of treatment weighted (IPTW) estimator.
To see the relation between the standardization with the total group as the standard and the marginal structural model, we write SRR T as:
In the simple stratified analysis, the conditional probability of receiving exposure for subjects in the kth stratum is n k /N k , and hence the conditional probability of receiving nonexposure is 1 Ϫ n k /N k ϭ m k /N k . It is obvious that the standardized risk ratio with the total group as the standard, SRR T , is identical to the IPTW estimator in the marginal structural model (see Appendix 1) . Table 3 displays this process when we applied the IPTW method to the stratified data given in Table 2 . Table 3 Sato and Matsuyama Epidemiology • Volume 14, Number 6, November 2003 gives the observed number of women with each of the possible combinations of lymph node metastasis (LYM), tamoxifen use (TAM), and recurrence of breast cancer (RE-CUR) as well as the IPT weights w T ϭ 1/P(E ϭ e|Z ϭ z). For example, P(TAM ϭ 1|LYM ϭ 1) is calculated in the LYM ϭ 1 stratum as the total number of tamoxifen-used (exposed) women (1215) divided by the total number of women (1975) which yields 0.615. Then, the IPT weights in the LYM ϭ 1 stratum are 1.63 ϭ 1/0.615 for the exposed women and 2.60 ϭ 1/(1 Ϫ 0.615) ϭ 1/0.385 for the unexposed women. The column "Pseudo No. Total" represents the number of women in the weighted pseudo-population for each combination of (LYM, TAM, RECUR). Table 4 displays the crude data from the pseudo-population created by the IPT weights. The crude risk ratio is 0.83, which is identical to the SRR T . We can interpret the marginal structural models associated with the IPTW estimator as a nonparametric multivariate extension of the standardization method with the total group as the standard.
Proposed Weights
Although the IPTW estimator is useful for estimating the population intervention effects, the standardization method with either the exposed group or the unexposed group as the standard is also useful in epidemiologic applications. We show that with the modified weights, we obtain the extensions of SMR or SRR U in the marginal structural models. Similar to SRR T , SMR can be rewritten as:
The weights implicitly used in SMR can be interpreted as the inverse of the conditional probability of receiving the subject's own exposure multiplied by the conditional probability of receiving exposure regardless of the subject's actual exposure status (see Appendix 1) . This leads to a new weight for the ith subject:
We call this the SMR weight. In the SMR weight, the denominator works to control confounding in the same way as in the inverse probability of treatment weights; the numerator reweights the pseudo-population to give it the distribution of covariates in the target population (here, the exposed).
The weighted analysis of the association model (2) with new weights (3) gives unbiased estimates of the parameters in the following marginal structural model:
where "set E ϭ e, E ϭ 1" means what would have occurred in the exposed group had the exposed group taken the exposure e. The resultant estimator for exp( 1 ), which is LYM ϭ 1 (positive for lymph node metastasis at surgery), 0 (negative); TAM ϭ 1 (exposed to tamoxifen), 0 (unexposed); RECUR ϭ 1 (recurrence of breast cancer), 0 (no recurrence). MSMs for Standardization consistent with causal parameter exp(␤ 1 ), has the interpretation as a nonparametric multivariate extension of the standardized mortality ratio. For the exposed subjects the weight w Ei is always 1 and for the unexposed subjects it is the conditional exposure odds. Table 3 also displays the SMR weighting scheme. The SMR weight w E in the LYM ϭ 1 stratum is calculated as the total number of exposed women (1215) divided by the total number of unexposed women (760), which yields 1.60. The last column, "Pseudo No. Exposed," represents the number of women in the SMRweighted pseudo-population. Table 5 displays the crude data from the pseudo-population created by the SMR weights. The crude risk ratio is 0.85, which is identical to SMR. Parallel arguments give the extension of the standardization method with the unexposed group as the standard. The marginal structural model can be written as:
log P͑D ϭ 1|setE ϭ e, E ϭ 0͒ ϭ ␥ 0 ϩ ␥ 1 e, and we have unbiased estimates of (␥ 0 , ␥ 1 ) by the weighted analysis of the association model (2) with weights
In Table 6 , a summary of different sets of weights is given when we use the logistic model
in the estimation of propensity scores. Here we include a constant 1 in z i so that the logistic model can contain the intercept. Table 7 shows crude person-time data from an observational study of the effect of postoperative tamoxifen on the recurrence of breast cancer. 14 The study subjects were 6148 women who had been diagnosed with unilateral primary breast cancer and who had received surgical treatment between 1982 and 1990 at 9 institutions in Japan. The study was initiated in 1995 and the end of follow up was March 1996. Information on each patient was retrospectively obtained from medical records or a prospectively compiled computer database at each institution. Among 6148 women, information on recurrence was obtained for 4901 women shown in Table 7 as well as Table 2 . The crude rate ratio was 1.11 with a 95% confidence interval of 0.97-1.27. There was no protective effect of adjuvant tamoxifen use on the recurrence of breast cancer. However, because the exposure to adjuvant tamoxifen use was not randomized, the crude results might have been confounded as in the previous risk-ratio analyses.
Tamoxifen Use and Recurrence of Breast Cancer
We conducted weighted Poisson regression analysis 1 in which the recurrence rate r was modeled as:
with the estimated SMR weights ŵ Ei and where e is the exposure indicator (1, exposed to tamoxifen; 0, unexposed). The propensity score for each subject i was estimated by the logistic model, providing the estimated SMR weights. We chose the following 4 covariates as confounding factors: age at surgery, stage of breast cancer, lymph node metastasis, and menopausal status. These variables were included in the logistic model. Table 8 shows the crude data from the pseudo-population created by the SMR weighting. The crude rate ratio in Table 8 is an unbiased estimate of the causal rate ratio, provided that there were no unmeasured confounders after controlling for these 4 covariates. We can fit this weighted Poisson regression model using Proc Genmod in SAS (version 8.2, SAS Institute Inc, Cary, NC). The logarithm of each observed person-year is included as the offset variable in the option of "model" statement, and each estimated weight is specified in the "weight (or scwgt)" statement. The robust variance estimate can be obtained by specifying the "repeated" statement with the patient identification variable (ID) and the independent working correlation matrix ("repeated subject ϭ ID/type ϭ ind"). SAS code for the analysis of this example is given in Appendix 2. Estimated rate ratio was 0.89 with a robust 95% confidence interval of 0.78-1.02. Compared with the crude analysis given in Table 7 , the adjusted analysis gave a remarkable shift to show the protective effect of adjuvant tamoxifen use.
In the calculation of a confidence interval, we used the robust variance estimate. It provides a conservative confidence interval for , which is guaranteed to cover the true at least 95% of the time in large samples. 10, 15 In the weighted analysis, the fitted association models (2) or (5) assume risk or rate homogeneity within the same exposure subgroup. However, in the definition of the causal risk (rate) ratio, we need not assume such homogeneity. Thus, the variance functions of the fitted association models are misspecified, and hence the model-based variance estimate is not valid. For example, the variance estimate of log SMR from the stratified data given in Table 2 is 0.0034, whereas the model-based and the robust variance estimates of the SMR-weighted 1 are 0.0032 and 0.0037, respectively.
We conducted the usual Poisson regression analysis adjusted by the same 4 covariates. The estimated constant rate ratio is 0.87 with a 95% confidence interval of 0.77-1.00. Because possible effect-measure modification was anticipated, the interaction term between tamoxifen use and lymph node metastasis was added to the previous model. The estimated rate ratios with and without lymph node metastasis are 0.95 and 0.72; for the interaction term, P ϭ 0.06. With this effect-measure modification, we need to have some population-averaged rate ratio estimator. The IPTW estimator proposed by Robins and colleagues 10, 11 is one such measure when the target population is the total group, whereas the SMR-weighted estimator is also such a measure when the target population is the exposed subgroup.
Standardization using marginal structural models is based on differences in the baseline distribution of confound-ers. Therefore, it entirely avoids the problem, noted by Greenland, 16 of adjustment by person-time, which might be considered an outcome variable in the usual standardization approaches for stratified person-time data.
DISCUSSION
The marginal structural models with the inverse probability of treatment weights give the nonparametric multivariate extension of the standardization method with the total group as the standard population. We have shown that other choices of weights give the extension of the standardization method with other groups as the standard. All the weights can be calculated using the estimation of the propensity scores ( Table 6 ). We primarily considered the estimation of ratio measures in the previous sections. It is straightforward to apply the proposed weights to the estimation of difference measures. 10 Marginal structural models with various sets of weights can be used as a useful tool for the standardization methods, depending on the appropriate choice of target population.
where P(Z ϭ z) is the distributions of Z in the entire study (total) population. The target population might sometimes be completely external.
When the total population is the target population, P(Z ϭ z|target population) ϵ P(Z ϭ z) and we have
This leads to the inverse probability of treatment weighting. Similarly, when the exposed group is the target population, P(Z ϭ z | target population) ϵ P(Z ϭ z|E ϭ 1) and
The last term in the right-hand side is the SMR weights given in the text. When the unexposed group is the target population, P(Z ϭ z | target population) ϵ P(Z ϭ z|E ϭ 0) and P͑D ϭ 1͉set E ϭ e,E ϭ 0͒ 
Appendix 2
In this appendix, we provide SAS code to obtain the nonparametric multivariate extension of SMR described in the text. The following code is organized as follows. First, we use Proc Logistic to fit the logistic model in the estimation of propensity scores. Second, we use a SAS data step to calculate the proposed SMR weights for each subject from the estimated propensity scores of previous logistic model. Last, we use Proc Genmod to fit the weighted Poisson regression model that estimates the causal rate ratio.
The data file (SMR1) contains 1 record per woman. In the following code, the variable "ID" is the patient identification number and the variable "TAM" is a binary variable indicating whether a patient was exposed (TAM ϭ 1) or unexposed (TAM ϭ 0). The variables "AGE," "STAGE," "LYM," and "MENO" are age at surgery, stage of breast cancer, lymph node metastasis, and menopausal status, respectively. The variable "RECUR" is the binary outcome of recurrence. The variable "LOGPT" is the logarithm of observed person-times for each subject. 
